cyrilzakka/clinical-trials huggingface dataset:
7.0T Magnetic Resonance Imaging Study of Parkinson's Disease

This clinical trial study is conducted to detect the imaging characteristics of the patients with Parkinson's diseases (PD) by 7-Tesla (7T) magnetic resonance imaging (MRI).

In this study,we explored the imaging characteristics of PD. First, with the advantage of 7T, we detect the slight changes of PD with short diseases history compared with the healthy. Second, we investigate the different imaging characteristics in subtypes of PD, finding the effective neuroimaging biomarkers to distinguish different subtypes of PD. Finally, we take long time follow-up to evaluate the correlation between the imaging changes and clinical score alteration in PD.

Eligibility Criteria:
Inclusion Criteria:

* the patients with PD who was diagnosed by the experienced neurologist specializing in movement disorders

Exclusion Criteria:

* the patients with brain disorders such as cerebrovascular disease, brain tumors, epilepsy, other neurodegenerative disease;
* psychiatric disorders with impaired cognitive function;
* contraindications to MRI.
Risk Factors and Disorders Linked to Uterine Adenomyosis on MRI in Reproductive-Age Women

The goal of this observational case-control study is to identify risk factors and associated conditions related to adenomyosis in women of reproductive age.

The main questions it aims to answer are:

Is there an association between a history of uterine surgery and the occurrence of adenomyosis? Does a higher prevalence of endometriosis or increased number of pregnancies correlate with adenomyosis? Researchers will compare women with MRI-confirmed adenomyosis to a control group of women who underwent pelvic MRI for other reasons but were not diagnosed with adenomyosis to see if there are significant differences in risk factors such as endometriosis, number of pregnancies, and history of uterine surgery.

Participants will:

Undergo pelvic MRI with and without intravenous contrast Provide information on factors such as age, smoking, number of pregnancies, history of uterine surgery, and coexisting conditions like leiomyoma and ovarian cysts This study aims to inform better management strategies for reducing the incidence of adenomyosis by targeting modifiable risk factors.


Eligibility Criteria:
Inclusion Criteria:

* Women of reproductive age (18-50 years).
* Patients who underwent pelvic MRI for clinical indications.
* MRI-confirmed diagnosis of adenomyosis (for the case group).
* Patients without adenomyosis confirmed by MRI (for the control group).
* Willingness to participate and provide informed consent.

Exclusion Criteria:

* Women outside the reproductive age range (under 18 or over 50 years).
* Pregnancy or lactation at the time of MRI.
* Previous hysterectomy or other major uterine surgeries.
* Presence of malignancies or other serious conditions that could interfere with the study.
* Inability to undergo MRI due to contraindications (e.g., metal implants, pacemakers).
* Incomplete or missing MRI data.
* Non-consent to participate in the study.
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.


Eligibility Criteria:
Inclusion Criteria:

* Subject has the ability to understand, able, willing to comply with study procedures and follow up visits, and has provided written consent.
* Pathologic evidence of solid tumor.
* Failed standard therapy and deemed by the Investigator to be suitable for participation into the trial.
* Laboratory values (obtained within 10 days prior to enrollment): ANC: \>= 1.5 × 109/L; Platelets: \>= 100 × 109/L; Hemoglobin: \>= 10.0 g/dL (without transfusions); Bilirubin: within normal range; AST, ALT, and alkaline phosphatase: \<= 2.5 x ULN without tumor liver involvement; Serum creatinine: within normal limits; Calculated creatinine clearance: \>= 60 mL/min/1.73 m2 for patients with creatinine \> Institutional Normal Values; PT/PTT/INR: within normal limits.
* Have IHC evidence of phospho-MET expression on tumor material no more than 12 months old. This is a requirement only for entry into the MTD dose expansion phase.
* Have no residual toxic effects of previous therapy, and undergo a washout period of at least 5 half-lives from the time of administration of the previous therapy.

Exclusion Criteria:

* Pregnant, lactating, or may become pregnant.
* Cardiac disease requiring medical therapy.
* Have had a major surgery within 4 weeks prior to Day 1 of the study
* Have an active, uncontrolled bacterial, viral, or fungal infection that requires ongoing systemic therapy.
* Have a known active infection with HIV, hepatitis B or C.
* Have psychiatric or seizure disorders that would require therapy or interfere with study participation.
* Have other severe concurrent nonmalignant disease that could compromise protocol objectives, including malabsorptive conditions.
* Patients receiving prohibited medications as listed in Appendix E, including drugs categorized as strong inhibitors of CYP3A4 and A5 and drugs known to have a high potential risk of liver toxicity.
* Have known allergy to SGX523 formulation or its excipients (croscarmellose sodium, lactose monohydrate and magnesium stereate).
* Patients receiving anti-coagulant therapy.
Effectiveness of a Breathing and Relaxation Technique in Antenatal Education

The aim of this randomised controlled trial is to compare the effects of an antenatal education class including a breathing and relaxation technique on self-efficacy compared to a standard antenatal education class without a focus on breathing and relaxation techniques.

Antenatal education classes were developed to inform expectant mothers about pregnancy, labour and birth and the postpartum period with the aim of improving pregnancy and childbirth experience. They were based, for example, on concepts of Lamaze and Grantly Dick-Read. Studies indicate positive emotional effects on labour and birth outcomes in women who attended antenatal education classes. This includes lower levels of fear of childbirth, lower rates of caesarean birth at the women's request, a higher rate of spontaneous births, and a stronger involvement of the partner, better chances of initiating breastfeeding, a lower likelihood of developing depression symptoms during the postpartum period. There is limited evidence on the link between birth preparation and neonatal outcomes. Considering recent evidence suggesting that antenatal education classes may positively influence maternal and neonatal birth outcomes, we intend to analyse an antenatal education class focusing on a breathing and relaxation technique and assess the impact of such a class on self-efficacy, as well as other maternal and neonatal birth outcomes.

Eligibility Criteria:
Inclusion Criteria:

* pregnant women with a singleton low-risk pregnancy
* receiving antenatal care
* being willing to attend an antenatal education class
* planning a vaginal birth
* sufficient oral and written German language knowledge

Exclusion Criteria:

* women, who plan an elective caesarean section
* pregnant with multiples
* do not have sufficient oral and written German language knowledge
Hypothyroidism Treated With Calcitonin

Some people with hypothyroidism have persistent symptoms despite adequate treatment with thyroid hormones. We are testing whether giving calcitonin to such people will improve their quality of life.

It is known that a proportion of patients with hypothyroidism despite serum TSH levels being within the normal reference range, may continue to express symptoms of hypothyroidism. Common symptoms include fatigue, muscle pain, weight gain, and mood changes. Saravanan et al. reported in a large community-based survey that patients on levothyroxine even with a normal TSH showed significant impairment in psychological well-being compared with age- and sex-matched controls. These patients are challenging to manage and are often unhappy with they care.

Established treatment of hypothyroidism is levothyroxine. Thyroid follicular cells synthesize and secrete thyroxine and triiodothyronine. However, even when people are receiving adequate levothyroxine replacement therapy, their quality of life may not improve. Calcitonin (CT) is also produced by the thyroid gland, parafollicular cells. Their levels are not tested in hypothyroidism because the exact role of calcitonin in human health and disease is not fully known. CT has long been thought to play an important role in bone and mineral homeostasis, particularly with respect to its ability to regulate calcium metabolism. CT has been found in fish, reptiles, birds, and mammals. Salmon-derived CT is 50-100 times more potent than human CT. Hence, salmon CT (sCT) has been used for medicinal purposes.

There is a need for further research in order to understand the nature of persisting symptoms in patients on T4 monotherapy despite a serum TSH within the reference range. Calcitonin has been shown to alleviate pain in patients with bone or mineral disorders. To date, the use of calcitonin for relief of hypothyroid symptoms has not been studied.

Eligibility Criteria:
Inclusion Criteria:

* Normal TSH on levothyroxine therapy

Exclusion Criteria:

1. pregnant or 6 months post partum
2. Current or previous thyroid cancer
3. Congenital hypothyroidism
4. any tobacco use
5. prescribed proton pump inhibitors
6. prescribed steroids
7. taking armour thyroid, naturethroid, or any dessicated thyroid hormone
8. Unstable medical conditions (CKD, Cirrhosis etc)
9. pituitary disease
Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation

The incidence of atherosclerotic complications is increased after kidney transplantation. Traditional risk factors do not fully explain this increased risk. Atherosclerosis is an inflammatory disease in which all players in the immune response are involved. The impact of these immune responses is not well known in immunocompromised patients, particularly among organ transplant. Nevertheless, the work of our group suggest that innate and acquired responses through different mechanisms influencing the evolution of atheromatous disease after transplantation.

The investigators therefore propose to study the impact of the expansion of regulatory T cells on the risk of atherosclerotic complications after transplantation.

Since November 2008, the investigators began a multicenter, prospective study whose purpose is to study in detail the immunological mechanisms of atherosclerosis after transplantation via immunomonitoring cohort of renal transplant patients in the Grand East Interregion. It was planned to include 500 patients and to date a little more than half have been included. After completion of the blood test, the tubes are routed over the Biomonitoring Platform (CIC-BT 506 Besançon) and the samples are stored in CRB Dijon.

The atherosclerotic events are recorded prospectively. The investigators hope to implement as part of ORLY IS, a second study to determine the impact of an expansion of regulatory T cells on the risk of atherosclerotic events.

Our hypothesis is that a cell rate regulatory T below the median results in an increase of 5% of atherosclerotic complications.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female patients aged over 18 years
2. Patients receiving a renal transplant
3. Patients able to understand the benefits and risks of testing
4. Patients gave written informed consent.

Exclusion Criteria:

1. Inability to understand the advantages and disadvantages of the study; psychiatric disorders judged by the investigator to be incompatible with the inclusion in the study.
2. Immunosuppressive therapy immediately prior to transplantation
3. Cancer (except skin cancer) or malignant blood disease being treated; active infection; decompensated cirrhosis \[patients had cancer and considered as cured or in remission, patients with virus infection of hepatitis B or hepatitis C and having no cirrhosis may be included\].

This study is strictly non-interventional, participation in another study is not a cons-indication to the inclusion in this study and no exclusion period is required for inclusion in another study after inclusion in this study (Art L. 1121-12 (loi n°2004-806 du 9 Août 2004).
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.


Eligibility Criteria:
Inclusion Criteria:

* Adults, 18 years and older
* Histologically confirmed and measurable giant cell tumor (GCT)
* Recurrent GCT confirmed by radiology or unresectable GCT
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

Exclusion Criteria:

* Pateints for whom surgery to the affected limb/area is planned within 27 days after receiving 1st dose of denosumab
* Radiation to affected region within 28 days before enrollment to study
* Known diagnosis of osteosarcoma or brown tumor of bone
* Known history of second malignancy within the past 5 years, except for basal cell carcinoma or cervical carcinoma in situ
* Concurrent treatment with bisphosphonates, calcitonin, or interferon.

Other criteria also apply.
Clinical Test for Transtek Glass Body Analyzer

The clinical protocol of the clinical testing of this device:

1. Objective of the test: To verify the functions and efficiency of devices.
2. Test methods and procedures: Comparison Test.
3. DUT: Transtek Glass Body Analyzer, Model: GBF-830, GBF-835, GBF-950, and SA-15.
4. Comparison device: Scaleman Body Fat Scales, FS-148BW1 (Predicate Device).
5. Study endpoints: Transtek devices and the predicate device are substantial equivalence.
6. Statistical methodology used: Description of statistical methods.
7. Result: Efficiencies of Transtek devices and predicate device are in the same level.

Hospital Information The data was collected by West China Medical College Clinical Investigator Team at Wuhou District Hospital, No. 9 Tongzilin Road, Wuhou District, Chengdu 610041, P. R. China.

Investigator: Catharine Zhang, Nurse A; Vivian Luo, Nurse B; Dr. James Zhu, Sponsor.

Contact Dr. James Zhu Tel: +86 1330 8036568 Used Equipments DUT (Device Under Test): Transtek Glass Body Analyzer, GBF-830, GBF-835, GBF-950, and SA-15.

Reference Device: Scaleman Body Fat Scales, FS-148BW1 (Predicate Device). Test Protocol

1. Test Purpose:

   The aim of clinical test is to collect weight, body fat, total body water, bone mass, and muscle mass reading value which measured by DUT and reference device.

   Note: GBF-835 has not total body water, bone mass, and muscle mass functions. So it just collects weight and body fat data.
2. Target Subject:

   The subject database shall contain at least 25 male and 25 female subjects and all above 18 years old. Patient's population analysis is bellow.
3. Test procedures 1) Record the name, age, gender, and height of each subject. 2) Let subject seated calmly for two minutes before test, dry the feet. 3) Use device to measure weight, body fat, total body water, bone mass, and muscle mass; record reading value.

4) For each subject, repeat 3) to get 3 pairs measurements. 5) Repeat step 1) to 4) for every device (DUT: GBF-830, GBF-835, GBF-950, and SA-15; and reference device: FS-148BW1).

6) Repeat step 1) to 5) for each subject. 5. Note:

1. No motion and speaking are allowed during the measurement.
2. All DUT use the same algorithms, have the same number of electrodes and contact the patient at the same body locations (feet), and operate on the same frequency.
3. Test environment: Temperature: 20±1℃; Relative humidity: 40\~50%.

Eligibility Criteria:
Inclusion Criteria:

* male,female

Exclusion Criteria:

* below 18 years old
To Evaluate 24-hr Glucose After OD vs BD AZD1656

The purpose of this study is to compare the 24-hour glucose profiles in diabetic patients treated with metformin following once daily and twice daily oral dosing


Eligibility Criteria:
Inclusion Criteria:

* type II diabetes patients, female with non child-bearing potential
* Type 2 Diabetes Mellitus (T2DM) diagnosis confirmed by C-peptide \>0.3nmol/L and no Glutamic acid decarboxylase (GAD) antibodies at enrolment (screening)
* Treatment with metformin as single therapy for T2DM for at least 30 days prior to enrolment and the metformin dose must have been unchanged during this period

Exclusion Criteria:

* History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
* Any clinically significant abnormality identified on physical examination, laboratory test or ECG, which in the judgement of investigator would compromise the subject's safety or successful participation in the clinical study
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis in MSA.


Eligibility Criteria:
Inclusion Criteria:

* Age\> 35 years old, gender is not limited;
* Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria;
* all patients had been ruled out of polyQ disease by genetic testing;
* Voluntarily participate in this study and sign the informed consent form.

Exclusion Criteria:

* pregnancy or breastfeeding;
* contraindications to MRI examination or inability to cooperate in completing neuroimaging examination;
* previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above);
* History of alcohol or drug abuse
Effects of Theraband Resistance Training on Muscle Strength in Coronary Artery Diseases

To compare the effects of Theraband Resistance Training with Conventional Resistance Training on muscle strength in coronary artery diseases


Eligibility Criteria:
Inclusion Criteria:

* Participants having a documented diagnosis of CAD, confirmed by a medical professional.
* Individuals with a history of myocardial infarction (heart attack), angina, or evidence of significant coronary artery stenosis.
* Stable CAD who were not experiencing acute coronary events, such as recent heart attacks or unstable angina.
* Patients who were able to perform exercises with TheraBand.
* Reduced muscle strength of upper limb/lower limb

Exclusion Criteria:

* Patients over the age of 75 years.
* Exclude individuals with a recent history of Theraband resistance training.
* Severe cardiovascular complications such as heart failure with reduced ejection fraction, severe arrhythmias, or uncontrolled hypertension.
* Patients with unstable conditions or cardiac episodes.
* Individuals who had undergone major cardiovascular surgery (e.g., coronary artery bypass grafting) within the last six months.
* Ejection fraction \< 40%
A New Oral Treatment For Type II Diabetes Mellitus

This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.

A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension

Eligibility Criteria:
Inclusion criteria:

* Women must not be pregnant and must not be breastfeeding.
* Have Type II diabetes.
* Not taking any medicine for diabetes, or taking one oral medicine for their diabetes.

Exclusion criteria:

* Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor.
High Intensity Interval Training in PCOS

Study objective is to determine the effect of High intensity interval training on psychological wellbeing, Anthropometrics and Quality of life in females with Polycystic Ovarian Syndrome


Eligibility Criteria:
Inclusion Criteria:

* females 18 to 45 years of age
* Diagnosed with PCOS based on Rotterdam criteria
* Ferriman and Gallway score of \>8 for hirsutism

Exclusion Criteria:

* Use of hormonal contraceptives or IUDs for contraception
* Taking metformin \<3 months prior to the inclusion
* Breast feeding mothers
* Type I or II DM
* Hypo/hyperthyroidism
* Regular high-intensity endurance or strength training (defined as ≥ 2 sessions of vigorous exercise per week), Physical ailments/injuries that limited exercise performance.
HKT-500 in the Treatment of Adult Patients With Ankle Sprain

The objective of this study is to demonstrate the multiple-dose efficacy and safety of HKT-500 for the treatment of ankle sprain.

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Mild to Moderate Ankle Sprain

Eligibility Criteria:
Inclusion Criteria:

* mild to Moderate Ankle Sprain

Exclusion Criteria:

* Any women of childbearing potential who has a positive urine pregnancy test, who is lactating, who is not surgically sterile (by tubal ligation or hysterectomy), who is not at least 2 years postmenopausal, or has not practiced an acceptable form of birth control (defined as the use of an intrauterine device with spermicide, a barrier method with spermicide, condoms with spermicide, subdermal implant, oral contraceptives, or abstinence) for at least 2 months prior to Visit 1.
Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)

Despite the use of various treatment strategies, poor response to ovarian stimulation remains a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus less likely to conceive with high risk of cycle cancellation. The aim of this study is to evaluate the effect of recombinant human GH administration to gonadotropins on clinical and laboratory ICSI outcomes in expected poor responders more and less than 35 years (Poseidon group 4 and 3 respectively).


Eligibility Criteria:
Inclusion Criteria:

1. Infertile women aged 20-45 years.
2. AFC \<5.
3. AMH level \<1.2 ng/ml.
4. Have two normal ovaries and normal uterine cavity.

Exclusion Criteria:

1. Body mass index (BMI) \>30 kg/m2.
2. Follicle Stimulating Hormone (FSH) \> 15 IU/L.
3. History of abnormal karyotype in one or both partners.
4. Endocrine, metabolic or autoimmune disorders, such as diabetes, thyroid disorder, and polycystic ovary syndrome (PCOS).
5. Women with a known medical disease (e.g. severe hypertension or hepatic disease).
6. Endometriosis.
7. Previous ovarian surgery.
8. Current or history of malignancies, chemotherapy or radiotherapy.
9. Severe male actor (total motile sperm count \<1×106 or normal morphology \<1%)